AbbVie Inc. (ABBV) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in North Chicago, IL, United States. Der aktuelle CEO ist Scott T. Reents.
ABBV hat IPO-Datum 2013-01-02, 55,000 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $372.01B.
AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a diverse portfolio of medicines across multiple therapeutic areas. The company's key products include HUMIRA for autoimmune diseases, SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis, IMBRUVICA and VENCLEXTA for blood cancers, and MAVYRET for hepatitis C, along with established brands such as Synthroid for hypothyroidism, Botox, Lupron, and Linzess for gastrointestinal conditions. AbbVie also offers specialized treatments in ophthalmology, neurology, and women's health, including eye care solutions and migraine therapies. Headquartered in North Chicago, Illinois, and incorporated in 2012, the company maintains research collaborations to advance its drug pipeline and expand its global reach.
